Alzheimer’s Disease

Key Research Findings

There is a significant amount of evidence regarding the therapeutic benefits of cannabinoids for the prevention and disease progression of Alzheimer’s and the associated symptoms. U.S. government funded research concluded that THC & CBD are powerful anti-oxidants and neuroprotectants.

Cannabinoids as antioxidants and neuroprotectants. (2003)
  • In 2003, the US Department of Health and Human Serves secured a medical patent on cannabinoids. The following is a summary: “The cannabinoids [CBD & THC primarily] are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa,on b-amyloid-induced toxicityin PC12 cells. (2004)
  • “The results reported that cannabidiol exerts a combination of neuro-protective, anti-oxidative and anti-apoptotic effects against b-amyloid-induced toxicity. Given the low toxicity of cannabinol shown in humans, this non-psychoactive component of marijuana may play an important role in counteracting neuronal cell death occurring in Alzheimers disease.” 
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. (2014)
  • “…endocannabinoid signaling has been demonstrated to modulate numerous concomitant pathological processes, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress.”
  • “Interestingly, neuronal damage increases the production of endocannabinoids, which may provide a defense mechanism against toxicity.”
Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. (2016)
  • Conclusion: “Adding MCO (Medical Cannabis Oil) to AD patients’ pharmacotherapy is safe and a promising treatment option.”
Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids
  • “The beta amyloid (Aβ) and other aggregating [pro-inflammatory]  proteins in the brain increase with age and are frequently found within neurons.  Cannabinoids such as tetrahydrocannabinol [THC] stimulate the removal of intraneuronal Aβ, block the inflammatory response, and are protective.” 
Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells (Article. 2016)
  • “The researchers found that high levels of amyloid beta were associated with cellular inflammation and higher rates of neuron death. They demonstrated that exposing the cells to THC reduced amyloid beta protein levels and eliminated the inflammatory response from the nerve cells caused by the protein, thereby allowing the nerve cells to survive.”

Sign up to receive emails about promotions, events, policy reform, and more!

You have successfully subscribed to Om's mailing list!

There was an error while trying to send your request. Please try again.

Om of Medicine will use the information you provide on this form to be in touch with you and to provide updates and marketing.